NIH ends ACTT-4 enrollment: Difference 'unlikely' between baricitinib, dexamethasone

Retrieved on: 2021-04-15 18:22:30

Tags for this article:

Click the tags to see associated articles and topics

NIH ends ACTT-4 enrollment: Difference 'unlikely' between baricitinib, dexamethasone. View article details on hiswai:

Excerpt

Remdesivir is currently approved by the FDA to treat COVID-19 in hospitalized patients aged 12 years and older. The FDA has granted an emergency ...

Article found on: www.healio.com